Jun
2026
Shanghai New International Expo Center
Visit us
stand E9C02, Finished Dosage
Zone

Techpool Bio-Pharma Co., Ltd.

Exhibitor at CPHI & PMEC China 2026
About Us

Techpool Bio-Pharma Co., Ltd. is a bio-pharmaceutical company dedicated to critical care medicine. We integrate R&D, manufacturing, and commercialization, and are actively seeking overseas distributors for our product portfolio. Our key products include: - Techpool Roan® (Ulinastatin for Injection): Acute Pancreatitis, Chronic Recurrent Pancreatitis, Adjuvant Rescue Therapy for Acute Circulatory Failure,(Septic Shock); - Kailikang® (Urinary Kallidinogenase for Injection) - Mild to moderate acute thrombotic cerebral infarction; - Urokinase (UK) for Injection and Iron Sucrose injection.

Read more Show less
Products
Show more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2015
  • Employees:
    1000 - 4999
Company types
Manufacturer/Innovator
View company profile
Contact info
  • +86 20 38972409
  • Website
  • 89 Gaopu Road, Gaotang Scientech, Industrial park, Tianhe, 510520, Guangzhou, Guangdong, China
Show contact info Hide contact info
Event information
CPHI & PMEC China 2026
  • 16 Jun 2026 - 18 Jun 2026
  • Shanghai New International Expo Center
  • Visit us at stand E9C02, Finished Dosage

Products Featured at CPHI & PMEC China 2026

  • Ulinastatin for Injection (UTI)

    Product Ulinastatin for Injection (UTI)

    UTI is a standard therapy for physicians and surgeons to treat the patients with Acute Pancreatitis, which can Protect the organ function and Reduce the incidence of complication and mortality.

    UTI is a unique treatment choice for physicians to treat the patients with ACF and Sepsis, in E...
  • Urinary Kallidinogenase for Injection (KLK)

    Product Urinary Kallidinogenase for Injection (KLK)

    Urinary Kallidinogenase for injection (KLK) is listed in Medical Insurance and Reimbursement List in China.

    KLK is the first choice to treat patients with Mild – Moderate Acute Thrombotic Cerebral Infarction, especially, for the patients who miss the treatment window of thrombolytic therapy, whic...